Latest Health News
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
June 05, 2026 16:05 ET | Source: Shattuck Labs, Inc. AUSTIN, Texas…
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
June 05, 2026 16:01 ET | Source: Jade Biosciences SAN FRANCISCO and…
Laguna Treatment Center Warns of Concerning Increase in Patients Seeking Help for Kratom Addiction
ALISO VIEJO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Laguna Treatment Center,…
Aja Health and Wellness Inc. Announces Agreement for the Sale of Assets of GOeVisit Service
June 04, 2026 18:11 ET | Source: Aja Health and Wellness Inc.…
Orange Plan Management Celebrates 4.9-Star Review Milestone, Reinforcing Its Role as a Leading NDIS Plan Manager in Australia
June 04, 2026 17:50 ET | Source: Orange Plan Management Brisbane, QUEENSLAND,…
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
June 03, 2026 21:55 ET | Source: BrightSpring Health Services, Inc. LOUISVILLE,…
POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding
Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1…
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and…
JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)
Favorable safety and tolerability profile, with rapid onset of clinical activity and…
